BofA raised the firm’s price target on AmerisourceBergen to $212 from $200 and keeps a Buy rating on the shares. The firm expects “a lot of positive group vibes” from the drug distributor group for upcoming quarter, the analyst tells investors in an earnings preview note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ABC:
- AmerisourceBergen price target raised to $192 from $174 at Mizuho
- Tenet Healthcare says Sun Park to succeed Dan Cancelmi as CFO
- Fly Insider: GameStop, Arteris among week’s notable inside trades
- AmerisourceBergen participates in a conference call with JPMorgan
- AmerisourceBergen 1.4M share Spot Secondary priced at $181.50